The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2020 Jun 24

PMID 32573516

Citations 4

Authors

Mei Tian

Xiuchun Yang

Yanfang Li

Sen Guo

Affiliations

Soon will be listed here.

Abstract

BACKGROUND The classical dynamin family consists of dynamin 1, 2, and 3, which have different expression levels in different tissues to regulate cell membrane fission and endocytosis. Recent studies have reported increased expression of dynamins in human cancer, but their expression in hepatocellular carcinoma (HCC) remains to be determined. This study aimed to investigate the expression of dynamin 1, 2, and 3 in tissue sections of human HCC using quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry. MATERIAL AND METHODS The expression of dynamin 1, 2, and 3 were investigated in 192 cases of HCC and 14 paired samples of HCC and adjacent normal liver tissue by qRT-PCR and immunohistochemistry. The clinical significance of dynamin 1, 2, and 3 were determined by correlating their expression levels with patient clinicopathological factors and survival rates. Independent prognostic factors were determined using the Cox regression hazard model. RESULTS In tissue samples from 192 patients with HCC, the expression of dynamin 1, 2, and 3 were upregulated in 41.15%, 29.69%, and 8.33% of cases, respectively. Dynamin 1 had a significantly increased mRNA expression level in HCC compared with adjacent normal liver tissues and was significantly correlated with alpha fetoprotein (AFP) levels, T stage, and TNM stage. Only dynamin 1 expression was correlated with the reduced overall survival (OS), and was identified as an independent prognostic biomarker of human HCC. CONCLUSIONS Upregulation of dynamin 1 at the protein and mRNA level was an independent prognostic biomarker of reduced OS in patients with HCC.

Citing Articles

Multiple machine-learning tools identifying prognostic biomarkers for acute Myeloid Leukemia.

Cheng Y, Yang X, Wang Y, Li Q, Chen W, Dai R BMC Med Inform Decis Mak. 2024; 24(1):2.

PMID: 38167056 PMC: 10759623. DOI: 10.1186/s12911-023-02408-9.

Cancer as a biophysical disease: Targeting the mechanical-adaptability program.

Nguyen L, Jacob M, Parajon E, Robinson D Biophys J. 2022; 121(19):3573-3585.

PMID: 35505610 PMC: 9617128. DOI: 10.1016/j.bpj.2022.04.039.

Exosomal microRNA-23a-3p contributes to the progression of cholangiocarcinoma by interaction with Dynamin3.

Ni Q, Zhang H, Shi X, Li X Bioengineered. 2022; 13(3):6208-6221.

PMID: 35200104 PMC: 8973721. DOI: 10.1080/21655979.2022.2037249.

DNM1: A Prognostic Biomarker Associated with Immune Infiltration in Colon Cancer-A Study Based on TCGA Database.

Hu M, Gu J, Su W, Zhang Z, Zhu B, Wang Q Biomed Res Int. 2021; 2021:4896106.

PMID: 34888380 PMC: 8651384. DOI: 10.1155/2021/4896106.

References

Khan I, Gril B, Steeg P . Metastasis Suppressors NME1 and NME2 Promote Dynamin 2 Oligomerization and Regulate Tumor Cell Endocytosis, Motility, and Metastasis. Cancer Res. 2019; 79(18):4689-4702. PMC: 8288561. DOI: 10.1158/0008-5472.CAN-19-0492. View

Zhou Y, Cao L, Li B, Zhang R, Sui C, Yin Z . Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol. 2011; 19(5):1700-6. DOI: 10.1245/s10434-011-1772-6. View

Takei K, Slepnev V, Haucke V, De Camilli P . Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol. 1999; 1(1):33-9. DOI: 10.1038/9004. View

Chernikova S, Nguyen R, Truong J, Mello S, Stafford J, Hay M . Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. J Clin Invest. 2018; 128(12):5307-5321. PMC: 6264728. DOI: 10.1172/JCI87191. View

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

Raja S, Shah S, Tariq A, Bibi N, Sughra K, Yousuf A . Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer. Oncol Lett. 2019; 18(1):219-226. PMC: 6539888. DOI: 10.3892/ol.2019.10310. View

Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y . Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther. 2013; 6:1417-24. PMC: 3797647. DOI: 10.2147/OTT.S51913. View

Wong B, Shea D, Mistriotis P, Tuntithavornwat S, Law R, Bieber J . A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells. Cancer Res. 2019; 79(11):2878-2891. PMC: 6548656. DOI: 10.1158/0008-5472.CAN-18-3369. View

Srinivasan S, Burckhardt C, Bhave M, Chen Z, Chen P, Wang X . A noncanonical role for dynamin-1 in regulating early stages of clathrin-mediated endocytosis in non-neuronal cells. PLoS Biol. 2018; 16(4):e2005377. PMC: 5927468. DOI: 10.1371/journal.pbio.2005377. View

10.

Marengo A, Rosso C, Bugianesi E . Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2015; 67:103-17. DOI: 10.1146/annurev-med-090514-013832. View

11.

Xu Y, Yang X, Lu X, Guo S, Liu Y, Iqbal M . Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun. 2014; 446(1):54-60. DOI: 10.1016/j.bbrc.2014.02.050. View

12.

Gong C, Zhang J, Zhang L, Wang Y, Ma H, Wu W . Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma. Am J Cancer Res. 2015; 5(2):702-13. PMC: 4396048. View

13.

Xu Y, Liu Z, Pan C, Yang X, Ning S, Liu H . HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. Oncogene. 2018; 38(6):868-880. DOI: 10.1038/s41388-018-0485-8. View

14.

Sun X, Cao H, Zhan L, Yin C, Wang G, Liang P . Mitochondrial fission promotes cell migration by Ca /CaMKII/ERK/FAK pathway in hepatocellular carcinoma. Liver Int. 2017; 38(7):1263-1272. DOI: 10.1111/liv.13660. View

15.

Sun R, Liu Z, Qiu B, Chen T, Li Z, Zhang X . Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. EBioMedicine. 2019; 47:142-155. PMC: 6796529. DOI: 10.1016/j.ebiom.2019.08.062. View

16.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

17.

Zhang W, He H, Zang M, Wu Q, Zhao H, Lu L . Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. Gastroenterology. 2017; 153(1):249-262.e2. DOI: 10.1053/j.gastro.2017.03.024. View

18.

Doherty G, McMahon H . Mechanisms of endocytosis. Annu Rev Biochem. 2009; 78:857-902. DOI: 10.1146/annurev.biochem.78.081307.110540. View

19.

Zhang Z, Chen C, Guo W, Zheng S, Sun Z, Geng X . DNM3 Attenuates Hepatocellular Carcinoma Growth by Activating P53. Med Sci Monit. 2016; 22:197-205. PMC: 4725618. DOI: 10.12659/msm.896545. View

20.

Ferguson S, De Camilli P . Dynamin, a membrane-remodelling GTPase. Nat Rev Mol Cell Biol. 2012; 13(2):75-88. PMC: 3519936. DOI: 10.1038/nrm3266. View